Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.

Fabrizio NelliDiana GiannarelliAgnese FabbriAntonella VirtuosoJulio Rodrigo Giron BerriosEleonora MarrucciCristina FioreMarta SchirripaCarlo SignorelliMario Giovanni ChilelliFrancesca PrimiValentina PanichiGiuseppe TopiniMaria Assunta SilvestriEnzo Maria Ruggeri

Published in: Cancer immunology, immunotherapy : CII (2023)

Our findings would strengthen the recommendation not to change anti-PD-1/PD-L1 treatment plans based on current or future immunization schedules, implying that all these patients should be closely monitored.

Keyphrases

sars cov
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
papillary thyroid
peritoneal dialysis
squamous cell carcinoma
health insurance
current status
patient reported outcomes
respiratory syndrome coronavirus
young adults
binding protein
patient reported
lymph node metastasis